We here demonstrate that senicapoc is efficacious (1) in vitro by blocking KCa3.1 in activated microglia, and (2) in vivo by reducing infarction, attenuating stroke-induced microglia activation, T cell infiltration, and inflammatory marker expression, and by improving neurologic recovery. The gene discussed is KCNN4; the disease is stroke disorder.